Blog

When people get sick, we often talk about the “weight” of the condition. We say a disease is heavy, or that it demands a huge budget.

But “being sick” is not a single state. Sociology splits this reality into three lenses: Disease, Illness, and Sickness. Naturally, when we measure the impact of a condition, we also split the approach into two different models: Burden of Disease (BoD) and Burden of Illness (BoI).

These two terms look like synonyms, but they are not. They come from different perspectives, measure different realities, and assign social responsibility in entirely different ways.

Let us look past the simple definitions. We need to examine their history, their spatial dimensions, and their structural flaws.

1. Space and Reality: The Static Grid vs. The Dynamic Ripple

The core difference between BoD and BoI is how they move through space.

Burden of Disease (Top-Down / Universal / Macro)
A static, standardized grid laid over a population. It measures the objective “Load” on the social machine.

Burden of Illness (Bottom-Up / Contextual / Micro to Macro)
A dynamic fire starting at the core of human experience. It ripples outward to erode finances, labor, and GDP.

Burden of Disease: The Metric of the System

• How it moves: Top-down. It sits exclusively on macro-structures.
• The Principle: BoD views a medical condition as an objective, third-person object. It deliberately ignores personal stories, emotions, and local culture. Instead, it treats a nation or a population as a biological machine. It measures the mechanical “Load” (過重) that a malfunction places on the state infrastructure. This model starts and ends strictly within population data.

Burden of Illness: The Metric of Lived Experience

• How it moves: Bottom-up. It starts with the individual and breaks vertically through the macro-system.
• The Principle: BoI starts with the first-person experience of suffering. This is the “Weight” (重量) carried by a living human. Crucially, this micro-level stress does not stay contained. Like falling dominoes, it leaks outward. It drains the family budget, causes absenteeism at the office, lowers daily performance (presenteeism), and ultimately hurts national productivity. It is a dynamic ripple. It turns a personal struggle into a market loss.

2. History: Governance vs. Markets

Neither metric came from pure science. Shifting political and economic needs in the late 20th century forced their creation.

The Rise of BoD: Neoliberal Governance (1990s)

Until the late 20th century, global health metrics only counted dead bodies through mortality rates. This data ignored conditions that do not kill but cause decades of severe impairment, like major depression, blindness, or back pain.

In 1993, the World Bank, the WHO, and Christopher Murray of Harvard launched the Global Burden of Disease (GBD) study. They wanted to compare completely different conditions. To do this, they invented a standardized, non-monetary currency: the DALY (Disability-Adjusted Life Year).

DALY = YLL(Years of Life Lost) + YLD(Years Lived with Disability)

The 1990s demanded economic efficiency. International aid organizations and welfare states needed a cold, uniform metric to allocate finite budgets. By condensing all suffering into a single number (DALYs), governments could run cost-effective analyses. They chose interventions that yielded the highest return on investment. It shifted the focus from measuring death to measuring the loss of life’s quality.

DALYs appear as neutral, scientific measures, but they embed value judgments at every step. They dictate which disabilities matter, how much they matter, and whose life-years count. Disability weights are not discovered in nature; they are constructed through expert panels, surveys, and cultural assumptions. The Global Burden of Disease is not merely a measurement tool. It is a political technology that actively shapes global health priorities.

The Rise of BoI: Pharmacoeconomics and Value (1980s)

At the same time, the pharmaceutical industry and Quality of Life (QOL) studies refined the term Burden of Illness.

As molecular biology advanced, drug companies produced revolutionary, highly targeted therapies. But these new drugs were highly expensive. Governments and insurance providers demanded proof. They asked: Why should we pay hundreds of thousands of dollars for this drug?

To justify high prices, drug companies and researchers had to look beyond basic survival rates. They had to show that a drug did more than fix a biological marker (Disease); it had to reduce the Illness burden. They designed “Burden of Illness Studies” to quantify the hidden costs: direct medical fees, out-of-pocket expenses for families, lost wages for caregivers, and the daily price of pain.

While pharmacoeconomics formalized BoI in the 1980s, the concept has deeper roots. In the 1970s, medical anthropologists like Arthur Kleinman reframed illness as a lived experience. During the 1980s and 1990s, patient movements—particularly HIV/AIDS activism and ME/CFS advocacy—politicized this experience. They demanded social recognition beyond bare biomedical markers. Thus, BoI developed as a hybrid concept: part lived experience, part economic calculation, and part political claim.

3. Five Intersections: A Cross-Disciplinary Critique

To evaluate BoD and BoI fairly, we must see how they function across different fields of thought. Both have distinct strengths and fatal blind spots.

• Philosophy of Science
  • Burden of Disease: Positivist abstraction. It prioritizes what can be standardized and counted. Strength: universal comparison. Weakness: erases lived depth.
  • Burden of Illness: Phenomenological grounding. It prioritizes what is felt and lived. Strength: captures reality. Weakness: hard to standardize.
• Ethics & Justice
  • Burden of Disease: Utilitarianism. It aims for the greatest happiness for the greatest number. It is efficient but cold; minorities vanish in averages.
  • Burden of Illness: Ethics of care. It focuses on immediate networks of vulnerability. It protects vulnerability but resists scaling.
• Economics
  • Burden of Disease: Macro-fiscal accounting. It measures the health of the system, tracking GDP loss and social security strain.
  • Burden of Illness: Micro-labor & shadow work. It measures the health of the home, tracking household ruin and unpaid caregiving.
• Anthropology
  • Burden of Disease: Etic (external). It de-contextualizes suffering. Disability weights ignore cultural context.
  • Burden of Illness: Emic (internal). It re-contextualizes suffering, mapping stigma, gender, class, and local narratives.
• Sociology
  • Burden of Disease: Top-down biopolitics. It operates as a tool for state surveillance, treating populations as variables to optimize.
  • Burden of Illness: Lateral biopolitics. It functions as a trap of self-governance, where individuals internalize productivity pressure.

4. The Social Architecture: Why There is No “Burden of Sickness”

We have Burden of Disease (the biological) and Burden of Illness (the experiential). Why does medical literature completely lack the term “Burden of Sickness” as a disease-specific metric?

The answer is simple: Sickness is a feature of the social infrastructure, not a feature of the disease.

Sickness represents the socially approved status given to an unwell person (the “Sick Role”). The institutional costs in this layer—like paid sick leaves, disability pensions, and insurance payouts—are highly volatile. They do not depend on the biological severity of the disease. They depend on the political and cultural laws of the country.

For example, the social cost of pelvic girdle pain is immense in Norway because the state funds long-term sick leave for it. In a country without such labor laws, like the United States, the Sickness cost is virtually zero. Yet, the Disease and Illness remain identical in both nations. Because the infrastructure itself determines these costs, macro-economics already tracks them under “National Healthcare Expenditure” or “Social Security Outlays.” There was never a need for a disease-specific term.

The absence of a “Burden of Sickness” metric is structural. Sickness is not a property of the disease or the patient. It is a property of the social system, reflecting labor laws, welfare regimes, and political choices. Because these infrastructures vary dramatically across countries, any attempt to quantify a universal, standardized “Burden of Sickness” would collapse under its own institutional relativism.

5. The Japanese Linguistic Trap: Fuka (負荷) vs. Futan (負担)

When translating these concepts into Japanese, we find a clear theoretical alignment in the characters—but a messy, confusing reality in practice.

• Disease Load –> 疾病負荷 (Fuka) = Engineering stress on a system
• Illness Weight –> 疾病負担 (Futan) = A heavy backpack carried by a human

In a perfect theoretical world:

• 疾病負荷 (Shippei-Fuka): Matches Burden of Disease. It uses Fu (負 – to bear) and Ka (荷 – a load/charge). Like electrical load or mechanical stress, it represents the engineering strain placed on state infrastructure by a biological anomaly.
• 疾病負担 (Shippei-Futan): Matches Burden of Illness. It uses Fu (負) and Tan (担 – to shoulder). It evokes a living human physically carrying a heavy backpack along a difficult path.

The Real-World Friction

But if you open Japanese public health white papers or medical economics journals, this clarity disappears.

While Shippei-Fuka is strictly reserved for GBD and DALY metrics, the term Shippei-Futan is heavily abused. Bureaucrats use it as a lazy translation for macro statistical data. Clinicians use it to describe a family’s emotional exhaustion. Economists use it to mean the financial strain on the national insurance pool (Zaisei-Futan – 財政負担).

In Japan, macro-systems, micro-homes, and state finances are all jammed into this single phrase: Shippei-Futan. Without a conscious effort to separate them, the unique suffering of the individual is easily swallowed by the fiscal anxieties of the state.

In Japanese policy discourse, the term Futan (負担) collapses three distinct layers—patient burden, caregiver burden, and fiscal burden—into a single word. This linguistic compression carries severe political consequences. The lived burden of illness is easily overshadowed by concerns about national insurance costs (Zaisei-Futan). As a result, the experiential dimension of the human being becomes structurally invisible.

Conclusion: The Creative Tension

Neither Burden of Disease nor Burden of Illness holds a monopoly on truth. Both are non-negotiable dimensions of the health ecosystem.

If we look only through Burden of Disease, we can build an efficient, mathematically optimized healthcare system. But we become blind to the people slipping through its grates. We create a world where a rare disease is ignored because its DALY impact is statistically irrelevant.

If we look only through Burden of Illness, we can deeply feel the tragic story of every broken life. But we lose the ability to organize society, build hospitals, or distribute limited resources fairly. We risk paralyzing the macro-policies that keep the entire community safe.

The true goal of studying health humanities and social sciences is not to choose between the “Static Grid” and the “Dynamic Ripple.” It is to stand firmly in the creative tension between them. We must acknowledge the numbers, honor the stories, and ensure that our tools of measurement never lose sight of the humanity they are meant to serve.

When we feel unwell, we reach for our phones and type the same familiar words: “I’m sick.”

In Japanese, byōki (病気) is a generous container. It can hold a mild cold, a chronic condition, a diagnosable pathology, or simply the vague heaviness of a day when the world feels too bright.

But in medical anthropology, sociology, and philosophy, “being sick” is not a single state.

It is a three‑layered phenomenon, each layer revealing a different truth about the human condition: Disease, Illness, and Sickness.

In an age when AI can analyze data in seconds and propose optimal treatment plans, this triad reminds us of something essential: health is never just biological. It is lived, narrated, negotiated. It is where the algorithm ends and the person begins.

1. Etymology: The Historical Origins of the Three Words

Before they became academic terms, these words belonged to the everyday lives of medieval Europeans. They carried the weight of discomfort, misfortune, and human fragility. Their evolution reflects the gradual separation of body, self, and society in Western thought. 

Disease: Away from Ease

Origin: Old French desaise (also attested as desease) — des- “away from” + aise “comfort/ease”. 

Literal Meaning: “Lack of comfort” or “physical inconvenience.”

Evolution: Until the late Middle Ages, disease referred broadly to discomfort, inconvenience, or misfortune. Only with the rise of anatomical science and pathological thinking did it narrow into its modern biomedical meaning.

Illness: The Texture of Feeling Ill 

Origin: Formed within English from ill (Old Norse illr, “bad/difficult”) + ‑ness.

Literal Meaning: “The state of being in bad shape.”

Evolution: In early modern English, illness could refer to moral badness or wickedness. By the late 17th century, it shifted almost entirely to bodily or mental unwellness.

Sickness: The Social Status of the Sick

Origin: Old English seocnes (seoc, “ill, feeble, grieving”).

Literal Meaning: “A weakened or unwell condition,” often blending physical frailty with emotional or spiritual distress.

Evolution: Long used interchangeably with illness, but 20th‑century sociology refined it to mean the socially recognized status of being unwell.

2. The Triad Model: Three Ways of Seeing a Malady 

In the late 20th century, scholars like Andrew Twaddle, Leon Eisenberg, Arthur Kleinman, Horacio Fabrega, and Byron Good reframed these words as three analytic perspectives.

“Patients suffer illnesses; physicians diagnose and treat diseases.”

— Leon Eisenberg (1977)

This distinction became foundational in medical anthropology and patient‑centered care.

Disease (The Medical Lens)

Focus: Biological, pathological, biochemical abnormalities

Characteristics: Objective, measurable, standardized

Goal: Cure — restoring physiological function or correcting the underlying abnormality

Illness (The Personal Lens)

Focus: The subjective, first‑person experience of being unwell

Characteristics: Phenomenological, narrative, deeply personal

Goal: Care — alleviating suffering and helping the person make sense of their experience

Sickness (The Social Lens)

Focus: Social identity, institutional labels, cultural expectations

Characteristics: Inter‑subjective, political, regulatory

Goal: Social management — allocating resources, defining rights, maintaining social order

3. When the Three Lenses Align—and When They Don’t 

Philosopher Bjørn Hofmann visualized these concepts as a Venn diagram. 

When all three overlap, the world feels coherent:

you feel unwell (Illness), the doctor finds a cause (Disease), and society acknowledges your condition (Sickness).

But often, the circles drift apart, creating ethical, clinical, and social dilemmas.

Pattern A — Disease (+), Illness (–), Sickness (–)

A biological abnormality exists, but the person feels fine and society does not treat them as a patient.

Examples: Asymptomatic hypertension, early‑stage carcinoma, viral incubation

Dilemma: Overdiagnosis and anxiety in otherwise healthy individuals

Pattern B — Disease (–), Illness (+), Sickness (–)

The person suffers, but tests show nothing abnormal.

Examples: Fibromyalgia, ME/CFS, Long COVID, early psychosomatic disorders

Dilemma: Patients are dismissed as “lazy” or “imagining it,” losing both medical validation and social support

Pattern C — Disease (–), Illness (–), Sickness (+)

No biological defect or subjective suffering, yet society labels the state as a medical condition.

Examples: Historical pathologization of homosexuality

Dilemma: Medicalization of social or moral categories

4. The Social Architecture of Being Sick 

The “Sick Role” (Talcott Parsons, 1951)

Parsons argued that sickness is a regulated social role with: 

Privileges:

• Exemption from normal responsibilities
• Exemption from blame

Obligations:

• Wanting to recover
• Seeking competent medical help and cooperating with it

Failure to meet these obligations risks losing legitimacy and being labeled as malingering. 

A Parallel with WHO’s Classic Framework

The triad mirrors the WHO’s 1980 model (later the ICF):

• Impairment (body level): Disease
• Disability (activity level): Illness
• Handicap (participation level): Sickness

This alignment underscores that health is simultaneously biological, experiential, and social. 

5. Japan: A Culture Where “Byōki” Holds Everything 

To apply this triad to Japan, we must first acknowledge a linguistic truth: Japanese does not naturally separate these three layers. 

The Elasticity of Byōki 

In Japanese, byōki can refer to: 

• a cold
• a diagnosable pathology
• chronic conditions
• or simply “not feeling well today”

Unlike English, Japanese rarely distinguishes between:

• biological abnormality (disease)
• subjective suffering (illness)
• social recognition and institutional status (sickness)

This linguistic compression shapes social expectations. Without distinct terms for disease, illness, and sickness, the boundaries blur. 

The Struggle for Sickness Recognition

In many workplaces, saying “I don’t feel well” (illness) is insufficient.

A doctor’s note—proof of disease—is required to unlock social protections (sickness), such as:

• paid sick leave
• workplace accommodations
• Shōbyō‑teatekin (傷病手当金)

In Japan, sickness is tightly regulated by certification, often more so than in Western contexts.

The Stigma of Sickness in the COVID Era 

During the pandemic, infection became more than a biological event.

It became a social identity, sometimes a dangerous one.

People were judged not for how they felt, but for what they represented:

• risk
• irresponsibility
• contamination
• moral failure

This is sickness in its purest form:

the social meaning of being unwell, detached from biology or experience.

Conclusion: Balancing the Ecosystem of Health

None of these three lenses is superior. They are mutually dependent pieces of a larger ecosystem.

To heal the body, we must address disease.

To ease suffering, we must understand illness.

To protect the vulnerable, we must recognize sickness.

When we look at medicine through this balanced, flat perspective, we stop blaming doctors for being overly analytical, and we stop blaming patients for having subjective pain that science cannot yet map. By understanding where the boundaries of Disease, Illness, and Sickness lie, we can build a more empathetic, integrated approach to human suffering.

With the 2026 revisions shaping the landscape of healthcare policy, I felt the need to map out the current state of Japan’s HTA system. As someone working at the intersection of data and policy, this guide is my attempt to clarify how we measure “value” in modern medicine.

Introduction: The Concept of “Value for Money” in Medicine

Japan has a universal healthcare system that provides high-quality medical care to everyone. However, many ultra-high-cost drugs—like new cancer therapies and gene treatments—are appearing now. This makes it difficult to keep the national health insurance budget sustainable.

Therefore, Japan started the Health Technology Assessment (HTA) system in April 2019. The goal is to check “Value for Money.” The system ensures that the price of a drug matches the clinical benefit it gives to patients and the healthcare system.

Chapter 1. Japan’s Unique “Post-Reimbursement” Model

The Japanese HTA system is structurally different from many other countries.

1. Price Adjustment Instead of a Gatekeeper

In some countries like the UK, if a drug gets a negative HTA result, the insurance will not cover it. Japan is different. Japan puts patient access first. Therefore, almost all approved drugs get insurance coverage first. The government uses HTA as a “complementary tool” to adjust the drug’s price (up or down) after it is already on the market.

2. The Core Metrics: QALY and ICER

To measure “value” scientifically, Japan uses two main international metrics:

• QALY (Quality-Adjusted Life Year): This measures both the length of life (survival) and the quality of life (QOL). One QALY means one year of life in perfect health.
• ICER (Incremental Cost-Effectiveness Ratio): This formula calculates the extra cost needed to get one extra QALY compared to existing standard treatments (i.e., standard of care, or the chosen comparator).
  ICER = \frac{\text{Cost (New Drug)} – \text{Cost (Existing Treatment)}}{\text{Effect (New Drug)} – \text{Effect (Existing Treatment)}}

3. Thresholds for Value

In Japan, if the ICER is below 5 million yen per QALY, the drug is “cost-effective.” The government keeps its price. For cancer or rare diseases, the threshold increases to 7.5 million yen per QALY because these patients have high unmet needs.

Chapter 2. The 2026 (Reiwa 8) Reform: A New Era for HTA

The April 2026 reform updates how Japan evaluates drug costs. The evaluations are becoming more strict and dynamic.

1. The New Price Adjustment Formula

If a new drug does not show an additional benefit compared to existing treatments, the government uses a new formula. This formula matches the new drug’s price closer to the existing treatment’s price (the comparator price).

• New Formula:
  \text{Adjusted Price} = \text{Pre-adjusted Price} \times \frac{\text{Comparator Daily Drug Price}}{\text{Target Daily Drug Price}}
• 15% Reduction Cap: A very big price drop can make drug supply unstable. Therefore, the maximum price cut from this HTA formula is limited to 15% (the price will not go below 85% of the original price).

2. Dynamic Re-Evaluation (H3 Category)

HTA is not a one-time check at the start. Under the 2026 rules, the government can evaluate a drug again (under category H3) even after the first review is finished. This happens if there is important new clinical data or new global HTA results.

3. Terminology and Caregiving Costs

The government changed the term “Additional Benefit” to “Improvement in health outcome indicators relative to the comparator.” This avoids confusion with other drug pricing rules. Also, the 2026 rules give clearer instructions on how to include caregiving costs. This recognizes that good drugs can reduce the burden on family members.

4. Implementation Schedule

For drugs that report HTA results after April 2026, the price adjustments will wait until September 2026. This gives the government time to check the technical effects of the new reform before changing prices.

Chapter 3. Selection Criteria: The “H-Category” Framework

Not all medicines go through HTA. The government selects drugs based on their impact on the national health budget using five categories.

Category	Timing	Main Criteria
H1	At Listing	High-budget drugs (predicted peak sales >50 billion yen).
H2	At Listing	Predicted peak sales >10 billion yen and high innovation premiums.
H3	Post-Listing	Expanding products with sales over 5 billion yen, or re-designated items.
H4	Legacy	Large-market drugs listed before the 2019 policy started.
H5	Similarity	Follow-on drugs adjusted based on the result of a similar representative drug.

Exemptions: Drugs for ultra-rare diseases (designated intractable diseases) or pediatric conditions usually do not go through HTA. This ensures patients can get essential treatments quickly.

Chapter 4. Technical Guidelines for Analysis

The C2H (Center for Outcomes Research and Economic Evaluation for Health) checks the technical quality of the data.

• EQ-5D-5L Standard: Japan prefers to measure quality of life (QOL) using the EQ-5D-5L tool. Companies can convert other scales (“mapping”), but review committees check this very strictly because it introduces uncertainty.
• Perspective: The analysis must use the “Public Payer Perspective.” This includes public insurance costs and patient co-payments.
• Discounting: Future costs and health effects decrease by 2.0% per year to calculate their value today.

Chapter 5. International Comparison: 2026 Global Trends

Japan is changing its pricing formulas, but other major HTA bodies are also changing their policies in 2026.

Country	2026 Policy Outlook	HTA Role
Japan	15% cap on HTA price cuts; dynamic re-evaluation.	Adjusts prices after the drug is listed.
UK (NICE)	Increased the threshold from £20k-£30k to £25k-£35k per QALY in April 2026.	Decides if the insurance covers the drug (Gatekeeper).
Germany	Focuses on “added therapeutic benefit” for price talks.	Price negotiation based on evidence.

The UK’s NICE increased its threshold for the first time in over 20 years to support industry growth and patient access. This is different from Japan, which focuses on controlling costs with mathematical formulas.

Chapter 6. Real-World Evidence and Success Stories

Japan is using more Real-World Data (RWD), such as health insurance claims (receipt data), to confirm a drug’s value in real clinical practice.

• Success Case (Dapagliflozin): The government evaluated this SGLT2 inhibitor for Chronic Kidney Disease (CKD). The analysis combined clinical trial data with Japanese RWD. It proved that the drug significantly reduces long-term dialysis costs. The ICER was about 1.28 million yen per QALY. This is well below the 5 million yen threshold, proving the drug is highly cost-effective.

Conclusion

In 2026, Japan enters the “Second Stage” of its HTA system. Evaluating a drug’s value is now a dynamic process that lasts throughout its time on the market. The 15% reduction cap and the new re-evaluation rules mean that economic evidence must be strong not just at launch, but always. For everyone in the healthcare industry, showing long-term economic value with Japanese data is now the most important key to success.

For me, the true “art of learning” in this field is not just tracking the changing formulas, but understanding how these policies ultimately affect real-world well-being. Keeping a steady eye on this balance is a core part of my ongoing inquiry.

---

Disclaimer: The views and opinions expressed in this article are solely those of the author and do not necessarily reflect the official policy or position of any affiliated organizations.